Sale

Acromegaly Treatment Market

Global Acromegaly Treatment Market Share, Size, Forecast: By Diagnosis Type: GH and IGF-I Measurement, Growth Hormone Suppression Test, Others; By Treatment Type; By Diseases Type; By Route of Administration; By Treatment Centers; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Acromegaly Treatment Market Outlook

The global acromegaly treatment market size attained a value of USD 1.73 billion in 2023. The market is likely to witness further growth at a CAGR of 7.7% during the forecast period of 2024-2032 to attain a value of approximately USD 3.36 billion by 2032. The growth of the market can be attributed to the rising awareness about the disorder among healthcare professionals and patients.

 

acromegaly-treatment-market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America is Expected to Lead the Market for Acromegaly Treatment

North America, owing to the high demand for novel prescriptions, innovative products, and the presence of established players in the market, is expected to be the leading region for acromegaly treatment. The United States and Canada are the largest markets for acromegaly treatment; due to the growing population prevalence of the disease, the medical institutes are spreading awareness of treatments with the government introducing favourable policies. Furthermore, the rise in collaborations and effort in research and development by the established organisations to develop new products and innovative procedures are propelling the demand for treatment, which in turn, helps in market growth.

 

Asia Pacific is Proliferating with the Increased Funding for Healthcare

Asia Pacific is showing promising growth opportunities for the market. The region is going through industrialisation, and people are increasingly moving to urban areas seeking a better lifestyle, which shows the rising awareness among people. The government is increasing their healthcare expenditure to establish an improved infrastructure, and with development in various sectors, the spending power of people will simultaneously increase, which will further drive the market growth.

 

acromegaly-treatment-market-by-segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentations

Acromegaly is a hormonal disorder that develops in the pituitary gland, which increases growth hormone production. A non-cancerous tumour usually causes it. In acromegaly treatment, the goal is to restore the pituitary gland to function normally and produce normal levels of growth hormone.

By product, the market for acromegaly treatment includes:

  • Somatostatin Analogs (SSA)
  • Growth Hormone Receptor Antagonist (GHRA)
  • Others

The end-uses of the acromegaly treatment include:

  • Hospitals
  • Clinics 
  • Others

The regional markets for acromegaly treatment can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa, with North America leading the market and Asia Pacific being the fastest-growing region.

 

acromegaly-treatment-market-by-region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Prevalence of Diseases and New Medications Bolstering the Market Growth

As the population rises, the number of patients is increasing, and to provide safe and sufficient services, and the healthcare infrastructure is being developed continuously. Advancements in surgery and innovative alternate techniques are further broadening the market limits. The high cost of surgery can pose a little setback to market growth. However, governments are introducing favourable policies to spread medical treatment awareness. Multiple medical institutes and organisations are focusing on research and development to introduce novel medications, such as somatostatin analogs, which help stop the excess production of growth hormones. Additionally, with the launch of technologically advanced detection techniques like radiosurgery, radio imaging technologies provide cost-effective options for diagnosis with minimum side effects.

 

Key Players in the Global Market for Acromegaly Treatment

The report gives a detailed analysis of the following key players in the global acromegaly treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, investments, expansions of capacity, and plant turnarounds:

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Hikma Pharmaceuticals PLC.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Boehringer Ingelheim International GmbH.
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Lupin

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Diagnosis Type
  • Treatment Type
  • Diseases Type
  • Route of Administration
  • Treatment Centers
  • Treatment Channel
  • Distribution Channel
  • Region
Breakup by Diagnosis Type
  • GH and IGF-I Measurement
  • Growth Hormone Suppression Test
  • Imaging
  • Others
Breakup by Treatment Type
  • Medication
  • Radiation Therapy
  • Surgery
  • Others
Breakup by Diseases Type
  • Ectopic Acromegaly
  • Acromegaly Due to Growth Hormone
Breakup by Route of Administration
  • Oral
  • Parentals
  • Others
Breakup by Treatment Centers
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Rehabilitation Centers
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Hikma Pharmaceuticals PLC.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Boehringer Ingelheim International GmbH.
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Lupin

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Acromegaly Diseases Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Acromegaly Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Acromegaly Epidemiology (2016-2031)
    5.3    Europe Acromegaly Epidemiology (2016-2031)
    5.4    Asia-Pacific Acromegaly Epidemiology (2016-2031)
    5.5    Latin America Acromegaly Epidemiology (2016-2031)
    5.6    Middle East & Africa Acromegaly Epidemiology (2016-2031)
6    Global Acromegaly Treatment Market Overview
    6.1    Global Acromegaly Treatment Market Historical Value (2017-2023) 
    6.2    Global Acromegaly Treatment Market Forecast Value (2024-2032)
7    Global Acromegaly Treatment Market Landscape
    7.1    Acromegaly Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Cardiovascular Drugs Product Landscape
        7.2.1    Analysis by Diagnosis Type
        7.2.2    Analysis by Drug Type
        7.2.3    Analysis by Route of Administration
        7.2.4    Analysis by End User
        7.2.5    Analysis by Distribution Channel
8    Acromegaly Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Acromegaly Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Acromegaly Treatment Market Segmentation
    11.1    Global Acromegaly Treatment Market by Diagnosis Type
        11.1.1    Market Overview
        11.1.2    GH and IGF-I Measurement
        11.1.3    Growth Hormone Suppression Test
        11.1.4    Imaging
            11.1.4.1    Spine x-ray
            11.1.4.2    MRI of the brain, including the pituitary gland
            11.1.4.3    Echocardiogram
            11.1.4.4    Colonoscopy
            11.1.4.5    Others
        11.1.5    Others
    11.2    Global Acromegaly Treatment Market by Treatment Type
        11.2.1    Market Overview
        11.2.2    Medication
            11.2.2.1    Somatostatin analogues
            11.2.2.2    Dopamine agonists
            11.2.2.3    Growth hormone antagonist
            11.2.2.4    Others
        11.2.3    Radiation Therapy
        11.2.4    Surgery
        11.2.5    Others
    11.3    Global Acromegaly Treatment Market by Diseases Type
        11.3.1    Ectopic Acromegaly
        11.3.2    Acromegaly Due to Growth Hormone
    11.4    Global Acromegaly Treatment Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral 
        11.4.3    Parentals
        11.4.4    Others
    11.5    Global Acromegaly Treatment Market by Treatment Centers
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Specialty Clinics
        11.5.4    Homecare Settings
        11.5.5    Rehabilitation Centers
        11.5.6    Others
    11.6    Global Acromegaly Treatment Market by Treatment Channel
        11.6.1    Market Overview
        11.6.2    Public
        11.6.3    Private
    11.7    Global Acromegaly Treatment Market by Distribution Channel
        11.7.1    Market Overview
        11.7.2    Hospital Pharmacy
        11.7.3    Retail Pharmacy
        11.7.4    Online Pharmacy
        11.7.5    Others
    11.8    Global Acromegaly Treatment Market by Region
        11.8.1    Market Overview
        11.8.2    North America
        11.8.3    Europe 
        11.8.4    Asia Pacific
        11.8.5    Latin America
        11.8.6    Middle East and Africa
12    North America Acromegaly Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Acromegaly Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Acromegaly Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Acromegaly Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Acromegaly Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    F. Hoffmann-La Roche Ltd.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Mylan N.V.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Teva Pharmaceutical Industries Ltd.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Sanofi
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Pfizer Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    GlaxoSmithKline plc.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Novartis AG
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Merck & Co., Inc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Allergan
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    AstraZeneca
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Johnson & Johnson Private Limited
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Hikma Pharmaceuticals PLC.
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Bristol-Myers Squibb Company
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Bayer AG
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
    23.15    Boehringer Ingelheim International GmbH.
        23.15.1    Financial Analysis
        23.15.2    Product Portfolio
        23.15.3    Demographic Reach and Achievements
        23.15.4    Mergers and Acquisitions
        23.15.5    Certifications
    23.16    Dr. Reddy's Laboratories Ltd.
        23.16.1    Financial Analysis
        23.16.2    Product Portfolio
        23.16.3    Demographic Reach and Achievements
        23.16.4    Mergers and Acquisitions
        23.16.5    Certifications
    23.17    Gilead Sciences, Inc.
        23.17.1    Financial Analysis
        23.17.2    Product Portfolio
        23.17.3    Demographic Reach and Achievements
        23.17.4    Mergers and Acquisitions
        23.17.5    Certifications
    23.18    Eli Lilly and Company
        23.18.1    Financial Analysis
        23.18.2    Product Portfolio
        23.18.3    Demographic Reach and Achievements
        23.18.4    Mergers and Acquisitions
        23.18.5    Certifications
    23.19    AbbVie Inc.
        23.19.1    Financial Analysis
        23.19.2    Product Portfolio
        23.19.3    Demographic Reach and Achievements
        23.19.4    Mergers and Acquisitions
        23.19.5    Certifications
    23.20    Lupin
        23.20.1    Financial Analysis
        23.20.2    Product Portfolio
        23.20.3    Demographic Reach and Achievements
        23.20.4    Mergers and Acquisitions
        23.20.5    Certifications
24    Acromegaly Treatment Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for acromegaly treatment attained a value of nearly USD 1.73 billion.

The market is projected to grow at a CAGR of 7.7% between 2024 and 2032.

The market is estimated to witness healthy growth in the forecast period of 2024-2032 to reach USD 3.36 billion by 2032.

The increasing prevalence of diseases among the growing population, technological advancements, and increasing investment in healthcare are the major industry drivers.

The players' key industry trends are technological advancements and favourable government policies to reduce treatment expenses.

The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America being the leading region in the market and Asia Pacific growing at an exponential rate.

The different products in the market include somatostatin analogs (SSA) and growth hormone receptor antagonist (GHRA), among others.

The end-users for acromegaly treatment in the market include Hospitals and Clinics, among others.

The major players in the industry are Novartis AG, Ipsen Biopharmaceuticals, Inc., Chiasma, Inc., Pfizer Inc., and Ionis Pharmaceuticals, Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER